Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

SPSIPB Versus SAPB for Postoperative Analgesia After Minimally Invasive Repair of Pectus Excavatum

6 juli 2026 bijgewerkt door: Ulgen Zengin, Marmara University

Comparison of the Postoperative Analgesic Effects of Serratus Posterior Superior Intercostal Plane Block and Serratus Anterior Plane Block After Minimally Invasive Repair of Pectus Excavatum: A Prospective Observational Cohort Study

This prospective observational cohort study will compare postoperative analgesic outcomes in patients undergoing minimally invasive repair of pectus excavatum. Participants will be grouped according to the regional analgesia technique applied as part of routine clinical care: serratus posterior superior intercostal plane block or serratus anterior plane block. The primary outcome will be total opioid consumption during the first 24 hours after surgery. Secondary outcomes will include postoperative pain scores, rescue analgesic requirement, opioid-related adverse effects, patient satisfaction, mobilization time, and length of hospital stay.

Studie Overzicht

Gedetailleerde beschrijving

Pectus excavatum is the most common chest wall deformity in pediatric and adolescent patients and is characterized by posterior depression of the sternum and anterior chest wall. Although many patients are asymptomatic, corrective surgery is frequently performed during adolescence or young adulthood for cosmetic reasons and to improve body image and quality of life.

Minimally invasive repair of pectus excavatum involves the placement of a curved metal bar beneath the sternum. The bar is then rotated to elevate the sternum and correct the chest wall deformity. Despite favorable cosmetic and quality-of-life outcomes, postoperative pain remains a major clinical challenge after this procedure. Pain is mainly related to sternal elevation, pressure exerted by the bar, and repositioning of the ribs. Inadequate pain control may increase opioid consumption and prolong hospitalization. Higher opioid exposure may also lead to adverse effects such as nausea, vomiting, constipation, pruritus, and urinary retention.

Regional anesthesia techniques have become important components of multimodal postoperative analgesia in thoracic surgery. Thoracic paravertebral block, erector spinae plane block, and serratus anterior plane block are among the regional techniques commonly used for thoracic analgesia. Serratus anterior plane block has also been used for postoperative pain management after minimally invasive repair of pectus excavatum.

Serratus posterior superior intercostal plane block is a recently described ultrasound-guided interfascial plane block. The technique involves injection of local anesthetic between the serratus posterior superior muscle and the rib, usually at the level of the second or third rib. This block has been reported to provide analgesia in various thoracic and scapular pain conditions and has shown promising results in thoracic surgery.

The aim of this study is to compare the postoperative analgesic outcomes of serratus posterior superior intercostal plane block and serratus anterior plane block in patients undergoing minimally invasive repair of pectus excavatum. Because this is an observational study, the choice of regional analgesia technique will not be determined by the study protocol. The block technique will be selected by the attending anesthesiologist according to routine clinical practice. No randomization or protocol-driven assignment will be performed.

Studietype

Observationeel

Inschrijving (Geschat)

80

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Contact Back-up

  • Naam: Seniyye Ülgen Zengin, Associate Professor, MD
  • Telefoonnummer: +905057142443
  • E-mail: ulgen_t@yahoo.com

Studie Locaties

    • Istanbul
      • Istanbul, Istanbul, Turkije (Türkiye), 34722
        • Werving
        • Marmara University
        • Contact:
        • Contact:
          • Seniyye Ülgen Zengin, Associate Professor, MD
          • Telefoonnummer: +905057142443
          • E-mail: ulgen_t@yahoo.com
        • Hoofdonderzoeker:
          • Seniyye Ülgen Zengin, Associate Professor, MD
        • Onderonderzoeker:
          • Cem Özdemir, MD
        • Onderonderzoeker:
          • Meliha Orhon Ergün, Associate Professor, MD

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

  • Kind
  • Volwassen

Accepteert gezonde vrijwilligers

Nee

Bemonsteringsmethode

Niet-waarschijnlijkheidssteekproef

Studie Bevolking

The study population will include patients aged 15 to 25 years who are diagnosed with pectus excavatum and scheduled to undergo minimally invasive repair of pectus excavatum under general anesthesia. Patients who receive either bilateral serratus posterior superior intercostal plane block or bilateral serratus anterior plane block as part of routine perioperative analgesic care will be included.

Beschrijving

Inclusion Criteria:

  • Patients aged 15 to 25 years
  • Diagnosis of pectus excavatum
  • Scheduled to undergo minimally invasive repair of pectus excavatum under general anesthesia
  • Receipt of either bilateral serratus posterior superior intercostal plane block or bilateral serratus anterior plane block as part of routine perioperative analgesic care
  • Written informed consent obtained from the patient or, for patients younger than 18 years, from a legal guardian

Exclusion Criteria:

  • Refusal to participate in the study
  • Contraindication to regional anesthesia
  • Known allergy to local anesthetics or study analgesic medications
  • Chronic opioid use
  • Pre-existing chronic pain syndrome
  • Coagulopathy or use of anticoagulant therapy that contraindicates regional block application
  • Local infection at the block injection site
  • Neurological or psychiatric condition that may interfere with pain assessment
  • Incomplete perioperative or postoperative data
  • Conversion to another surgical technique or major intraoperative complication requiring a change in the routine analgesic protocol

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

Cohorten en interventies

Groep / Cohort
Interventie / Behandeling
Serratus Anterior Plane Block Group
Participants in this cohort will receive bilateral ultrasound-guided serratus anterior plane block as part of routine perioperative analgesic care.
Continuele intraoperatieve bewaking van de anesthesiediepte met behulp van het Bispectral Index (BIS)-apparaat. BIS-waarden worden gedurende de hele procedure geregistreerd om te helpen bij de titratie van anesthesiemiddelen en om de anesthesiediepte tussen onderzoekscohorten te standaardiseren. Het BIS-apparaat wordt alleen gebruikt voor bewaking en er worden geen apparaatgerelateerde onderzoeksprocedures uitgevoerd.
Andere namen:
  • BIS-bewaking
  • BIS
All participants will receive a standardized multimodal postoperative analgesia protocol. Patient-controlled analgesia with intravenous morphine will be used. The device will be programmed to administer 1 mg of intravenous morphine per demand, with a lockout interval of 10 minutes. Paracetamol will be administered as part of routine multimodal analgesia. If adequate analgesia cannot be achieved, 100 mg tramadol will be administered as rescue analgesia according to clinical need.
Bilateral ultrasound-guided serratus anterior plane block will be performed according to standard techniques described in the literature and routinely used in the clinic. Local anesthetic dosing will be determined according to institutional practice and safety limits. In bilateral applications, the total bupivacaine dose will not exceed 2.5 mg/kg.
Andere namen:
  • SAPB
  • SAP Blok
Serratus Posterior Superior Intercostal Plane Block Group
Participants in this cohort will receive bilateral ultrasound-guided serratus posterior superior intercostal plane block as part of routine perioperative analgesic care.
Continuele intraoperatieve bewaking van de anesthesiediepte met behulp van het Bispectral Index (BIS)-apparaat. BIS-waarden worden gedurende de hele procedure geregistreerd om te helpen bij de titratie van anesthesiemiddelen en om de anesthesiediepte tussen onderzoekscohorten te standaardiseren. Het BIS-apparaat wordt alleen gebruikt voor bewaking en er worden geen apparaatgerelateerde onderzoeksprocedures uitgevoerd.
Andere namen:
  • BIS-bewaking
  • BIS
All participants will receive a standardized multimodal postoperative analgesia protocol. Patient-controlled analgesia with intravenous morphine will be used. The device will be programmed to administer 1 mg of intravenous morphine per demand, with a lockout interval of 10 minutes. Paracetamol will be administered as part of routine multimodal analgesia. If adequate analgesia cannot be achieved, 100 mg tramadol will be administered as rescue analgesia according to clinical need.
Bilateral ultrasound-guided serratus posterior superior intercostal plane block will be performed according to standard techniques described in the literature and routinely used in the clinic. Local anesthetic dosing will be determined according to institutional practice and safety limits. In bilateral applications, the total bupivacaine dose will not exceed 2.5 mg/kg.
Andere namen:
  • SPSIPB
  • SPSIP-blok

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Total postoperative opioid consumption during the first 24 hours
Tijdsspanne: From the end of surgery to 24 hours postoperatively
Total opioid consumption during the first 24 hours after surgery will be recorded and expressed as intravenous morphine equivalents in milligrams.
From the end of surgery to 24 hours postoperatively

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Intraoperative opioid consumption
Tijdsspanne: From induction of anesthesia to the end of surgery
Total intraoperative opioid consumption will be recorded.
From induction of anesthesia to the end of surgery
Postoperative pain scores
Tijdsspanne: At arrival in the post-anesthesia care unit and at postoperative 6, 12, 24, and 48 hours
Pain intensity will be assessed using the Numeric Rating Scale, where 0 indicates no pain and 10 indicates the worst imaginable pain.
At arrival in the post-anesthesia care unit and at postoperative 6, 12, 24, and 48 hours
Patient satisfaction
Tijdsspanne: At postoperative 6, 12, 24, and 48 hours
Patient satisfaction with postoperative analgesia will be assessed using a 4-point Likert scale, where 0 indicates very dissatisfied and 3 indicates very satisfied.
At postoperative 6, 12, 24, and 48 hours
Incidence of Opioid-Related Adverse Effects
Tijdsspanne: From the end of surgery to 48 hours postoperatively
Presence of nausea, vomiting, pruritus, constipation, urinary retention, sedation, and respiratory depression. Adverse effects will be compared among the two groups.
From the end of surgery to 48 hours postoperatively
Duration of anesthesia
Tijdsspanne: Intraoperative period
The total duration of anesthesia will be recorded in minutes.
Intraoperative period
Duration of surgery
Tijdsspanne: Intraoperative period
The total duration of surgery will be recorded in minutes.
Intraoperative period
Time to mobilization
Tijdsspanne: From the end of surgery until the first documented ambulation, assessed within the first 48 postoperative hours
The time from the end of surgery to first mobilization will be recorded.
From the end of surgery until the first documented ambulation, assessed within the first 48 postoperative hours
Length of hospital stay
Tijdsspanne: Length of postoperative hospital stay, defined as the time from the end of surgery to hospital discharge, assessed up to 30 days postoperatively
The duration of postoperative hospitalization will be recorded.
Length of postoperative hospital stay, defined as the time from the end of surgery to hospital discharge, assessed up to 30 days postoperatively

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Studie stoel: Cem Özdemir, MD, Marmara University
  • Hoofdonderzoeker: Seniyye Ülgen Zengin, Associate Professor, MD, Marmara University
  • Studie directeur: Meliha Orhon Ergün, Associate Professor, MD, Marmara University

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

22 juni 2026

Primaire voltooiing (Geschat)

1 juni 2027

Studie voltooiing (Geschat)

1 juni 2027

Studieregistratiedata

Eerst ingediend

30 juni 2026

Eerst ingediend dat voldeed aan de QC-criteria

6 juli 2026

Eerst geplaatst (Werkelijk)

13 juli 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

13 juli 2026

Laatste update ingediend die voldeed aan QC-criteria

6 juli 2026

Laatst geverifieerd

1 juli 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Beschrijving IPD-plan

Individual participant data (IPD) will not be shared. The study involves clinical information collected under institutional ethical approval, and no consent was obtained for external sharing of identifiable or de-identified participant-level data.

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Ja

product vervaardigd in en geëxporteerd uit de V.S.

Ja

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren